Soligenix (SNGX) News Today $1.81 -0.03 (-1.68%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNGX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical TrialsJune 6, 2025 | finance.yahoo.comSoligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical TrialsJune 6, 2025 | globenewswire.comSoligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer TrialMay 24, 2025 | theglobeandmail.comSoligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial ResultsMay 20, 2025 | theglobeandmail.comSNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL…May 13, 2025 | finance.yahoo.comSOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deSoligenix Announces Recent Accomplishments And First Quarter 2025 Financial ResultsMay 9, 2025 | prnewswire.comSoligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast EpisodeMay 7, 2025 | theglobeandmail.comSoligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast EpisodeMay 7, 2025 | theglobeandmail.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.May 7, 2025 | finance.yahoo.comSoligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA FundingApril 30, 2025 | msn.comSolgenix shares rise on positive skin cancer treatment resultsApril 24, 2025 | investing.comFireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.April 24, 2025 | msn.comEQS-News: Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA FundingApril 24, 2025 | markets.businessinsider.comSNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses…April 15, 2025 | msn.comPositive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 WeeksApril 14, 2025 | prnewswire.comSoligenix (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma TreatmentApril 3, 2025 | theglobeandmail.comSoligenix Reports Publication Describing Preclinical Efficacy Of CiVax - Quick FactsMarch 27, 2025 | nasdaq.comSoligenix selects IBN to spearhead corporate communicationsMarch 26, 2025 | markets.businessinsider.comSNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…March 26, 2025 | msn.comIBN Initiates Coverage of Soligenix Inc.March 25, 2025 | globenewswire.comSoligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 VariantsMarch 25, 2025 | prnewswire.comSoligenix Trumps Year-End FinancialsMarch 21, 2025 | baystreet.caSoligenix Announces Recent Accomplishments and Year End 2024 Financial ResultsMarch 21, 2025 | prnewswire.comWhy Soligenix (NASDAQ: SNGX) Is ‘One to Watch’March 20, 2025 | theglobeandmail.comHyBryte™ Treatment Studies Presented at Two Medical Conferences in MarchMarch 6, 2025 | prnewswire.comSoligenix Aims To Push The Boundaries In Treating Rare DiseasesFebruary 26, 2025 | msn.comEQS-News: Soligenix Aims To Push The Boundaries In Treating Rare DiseasesFebruary 25, 2025 | markets.businessinsider.comSNGX: Presentation Highlights HyBryte Potential in CTCL…February 24, 2025 | msn.comEQS-News: Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026February 21, 2025 | markets.businessinsider.comSoligenix IncFebruary 18, 2025 | money.usnews.comSoligenix settles debt with Pontifax lendersFebruary 10, 2025 | msn.comSoligenix Repays Loan, Boosting Financial FlexibilityFebruary 10, 2025 | tipranks.comSoligenix on Way to Bio Conference in NYCFebruary 4, 2025 | baystreet.caSoligenix to Present at BIO CEO & Investor ConferenceFebruary 4, 2025 | prnewswire.comSoligenix (NASDAQ: $SNGX) Unveils Two-Pronged Approach To Tackle Rare Diseases & Unmet Medical NeedsJanuary 23, 2025 | msn.comSoligenix to Present at Upcoming Investor ConferencesJanuary 16, 2025 | prnewswire.comSNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…January 14, 2025 | msn.comHyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell LymphomaJanuary 14, 2025 | prnewswire.comSoligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trialDecember 19, 2024 | msn.comSNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway…December 17, 2024 | msn.comSoligenix initiates confirmatory Phase 3 trial of HyBryteDecember 17, 2024 | finance.yahoo.comSOLIGENIX, INC.: Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell LymphomaDecember 16, 2024 | finanznachrichten.deSoligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaDecember 16, 2024 | prnewswire.comSoligenix announces analysis from protocol HPN-CTCL-04December 3, 2024 | markets.businessinsider.comHyBryte™ Clinical Results Demonstrate Continued Improvement Post-TreatmentDecember 2, 2024 | prnewswire.comSoligenix forms European Medical Advisory BoardNovember 20, 2024 | markets.businessinsider.comSoligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell LymphomaNovember 19, 2024 | prnewswire.comSoligenix initiates Phase 2 clinical trial of SGX945 in Behcet’s DiseaseNovember 15, 2024 | markets.businessinsider.comSOLIGENIX, INC.: Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's DiseaseNovember 14, 2024 | finanznachrichten.de Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address SNGX Media Mentions By Week SNGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNGX News Sentiment▼1.430.89▲Average Medical News Sentiment SNGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNGX Articles This Week▼21▲SNGX Articles Average Week Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies X4 Pharmaceuticals News Today Cyclo Therapeutics News Today Ovid Therapeutics News Today Imunon News Today CASI Pharmaceuticals News Today Lisata Therapeutics News Today Enlivex Therapeutics News Today Q32 Bio News Today MIRA Pharmaceuticals News Today Natural Alternatives International News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNGX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.